Patent · US Active

Controlled release formulations

US10463624B2 · kind B2 · utility

0Cited by

36References

32Claims

0Family size

Assignee

Rhodes Pharmaceuticals L.P. · US

Inventors

Thinnayam N. Krishnamurthy · Scarborough, CA
Andrew Darke · Schreiber, CA

Key dates

Filing date	Sep 25, 2017
Grant date	Nov 5, 2019
Priority date	—
Expiry date	Sep 25, 2037

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P25/14
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.